<DOC>
	<DOC>NCT00808262</DOC>
	<brief_summary>Evaluation of the safety and the immune response induced by active immunization through a TNFa kinoid in patients with Crohn's disease.</brief_summary>
	<brief_title>Safety and Immunogenicity of a TNFa Kinoid in Patients With Crohn's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Subjects must have Active Crohn's Disease, as defined by a Crohn's Disease Activity Index (CDAI) score of &gt;220 but â‰¤400, with active Crohn's disease of ileum and/or colon (Other areas may be involved if ileum and/or colon are also involved)based upon either endoscopic, histologic and/or radiographic evidence Patients with active disease despite treatment with 5ASAs or sulfasalazine, corticosteroids (prednisone, budesonide, other), AZA or 6MP or cyclosporine or MTX or Tacrolimus, ; OR intolerant of 5ASAs or sulfasalazine; or intolerant of antibiotics; or intolerant of corticosteroids (prednisone, budesonide, other); or intolerant of AZA or 6MP or cyclosporine or MTX or Tacrolimus Patients might have previously responded to any prior antiTNF agents and then lost response OR might be intolerant of any prior antiTNF agents Positive skin reaction to challenge with Candida antigens Written informed consent Prior history of tuberculosis or positive chest X ray or positive purified protein derivative skin test or positive interferon gamma TB assay Signs or symptoms of clinically significant stricture of bowel. Total parenteral nutrition or elemental diet required for treatment of disease or support of short bowel syndrome Presence of an enteric stoma Imminent or urgent surgery required for infection, abscess, bleeding or any other cause relating to their Crohn's Disease or other condition History of malignancy. However, subjects with basal call carcinomas or less than 3 squamous cell carcinomas are allowed History of asthma or serious allergic condition (including history of seafood allergy) Serious local infection (e.g., cellulitis, abscess) or systemic infection (e.g., pneumonia, septicemia) within the 3 months prior to the first dose of study drug History of opportunistic infection excluding oral candidiasis on steroids Enteric infection as evidenced by positive stool C&amp;S, O&amp;P and C. difficile obtained during screening Any significant or decompensated cardiac, neurologic, liver, pulmonary or renal disease History of lymphoproliferative disorders Clinically significant abnormal hematology values, as determined by the investigator, for hematocrit, hemoglobin, white blood cell count or platelets Clinically significant abnormal blood chemistry values as determined by the investigator Current significant drug or alcohol abuse as determined by the investigator Positive for hepatitis C antibody or positive for hepatitis B surface antigen (HbsAg) or HIV infection Surgery within the previous 3 months (other than minor cosmetic surgery or minor dental procedures) Participation in a clinical study (including previous participation in this study) within the previous 4 months Had a primary nonresponse to any prior antiTNF agents as defined by the investigator OR received any prior antiTNF agents within the past 8 weeks prior to study entry Pregnancy and lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>anti-TNFa</keyword>
	<keyword>immunization</keyword>
	<keyword>kinoid</keyword>
	<keyword>crohn's disease</keyword>
</DOC>